Synthesis and SAR of novel quinazolines as potent and brain-penetrant c-jun N-terminal kinase (JNK) Inhibitors

Quinazoline 3 was discovered as a novel c-jun N-terminal kinase (JNK) inhibitor with good brain penetration and pharmacokinetic (PK) properties. A number of analogs which were potent both in the biochemical and cellular assays were discovered. Quinazoline 13a was found to be a potent JNK3 inhibitor (IC50 = 40 nM), with >500-fold selectivity over p38, and had good PK and brain penetration properties. With these properties, 13a is considered a potential candidate for in vivo evaluation.

Graphical abstractQuinazolines 3 and 13a were discovered as novel c-jun N-terminal kinase (JNK) inhibitors with good brain penetration and pharmacokinetic (PK) properties. Compound 13a is considered a potential candidate for in vivo evaluation.Figure optionsDownload full-size imageDownload as PowerPoint slide